- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07938086
Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test
Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Exercise Substudy (Six-Minute Walk Test) in Ambulatory Patients
This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient, second by second, according to oxygen saturation (SpO2), heart rate and respiratory rate measured by a pulse oximeter.
Adults with chronic respiratory disease who need oxygen during exertion perform two six-minute walk tests on the same day, 30 minutes apart: one with oxygen adjusted automatically by EMILY.AI and one with a fixed oxygen flow delivered through the same device. The order is randomized and participants do not know which test uses automatic titration.
The study compares the time spent within the target saturation range, desaturation, oxygen use, walking distance, breathlessness and participant preference between the two tests. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Background Patients with chronic respiratory disease often desaturate during exertion, and fixed-flow oxygen cannot follow the rapid changes in oxygen demand during walking and recovery. EMILY.AI combines a medical-grade oxygen valve with an edge-computing fuzzy-logic algorithm that sets the oxygen flow every second, with continuous logging of physiological signals and delivered flow.
Design Pilot, pragmatic, single-blind, randomized crossover study at Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain). Each participant performs two supervised six-minute walk tests (6MWT) according to the American Thoracic Society guideline, separated by 30 minutes of rest: one with automatic titration by EMILY.AI and one with a fixed flow set by the physician, delivered through the same device so that the participant cannot tell them apart. The order of the two tests is randomized. Each test includes 6 minutes of walking and 2 minutes of standardized recovery.
Safety The medical team knows the device configuration and supervises the valve throughout each test.
Measurements SpO2, heart rate and respiratory rate are recorded with medical-grade pulse oximeters (Nonin, Masimo or Nihon Kohden models), together with distance walked, Borg dyspnoea score, oxygen delivered and participant-reported comfort, breathlessness and preference.
The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and a substudy in a conventional hospital ward, registered separately.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Alba Naya Prieto, MD
- Numéro de téléphone: +34 915 50 48 00
- E-mail: alba.naya@fjd.es
Sauvegarde des contacts de l'étude
- Nom: Sarah Beatrice Heili Frades, MD, PhD
- Numéro de téléphone: +34 915 50 48 00
- E-mail: SHeili@fjd.es
Lieux d'étude
-
-
-
Madrid, Espagne, 28040
- Recrutement
- Hospital Universitario Fundación Jiménez Díaz
-
Contact:
- Sarah Beatrice Heili Frades Zimmermann MD, PhD
- Numéro de téléphone: +34 915 50 48 00
- E-mail: SHeili@fjd.es
-
Contact:
- Alba Naya Prieto, MD
- Numéro de téléphone: +34 915 50 48 00
- E-mail: alba.naya@fjd.es
-
Chercheur principal:
- Sarah Beatrice Heili Frades Zimmermann, MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged 40 to 90 years with a chronic respiratory disease.
- Indication for exertional oxygen therapy, defined as SpO2 below 88% during a six-minute walk test and/or resting respiratory failure (PaO2 below 60 mmHg).
- Able to understand the study and sign informed consent.
Exclusion Criteria:
- Decompensated acute or chronic disease with severe organ involvement, such as cardiovascular disease.
- Musculoskeletal or neurological disease preventing stable and safe walking.
- Comorbidities or treatments that, by intensity or dose, limit performance of the tests or interpretation of the results (such as alcohol use, beta-blockers, or other neurological or psychiatric drugs).
- Walking limitation preventing the six-minute walk test, or cardiovascular or connective tissue disease limiting accurate transcutaneous pulse oximetry.
- Pregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: EMILY.AI first, then fixed flow
First 6MWT with automatic titration by EMILY.AI; after 30 minutes of rest, second 6MWT with fixed-flow oxygen through the same device. |
Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery. Other names: EMILY.AI Smart Valve Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration. |
|
Expérimental: Fixed flow first, then EMILY.AI
First 6MWT with fixed-flow oxygen through the device; after 30 minutes of rest, second 6MWT with automatic titration by EMILY.AI. |
Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery. Other names: EMILY.AI Smart Valve Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of time with SpO2 within the target range
Délai: Day 1
|
Percentage of test time (6 minutes of walking plus 2 minutes of recovery) with SpO2, measured by pulse oximetry, within the predefined target range (88-92%), without delivering oxygen while SpO2 is above the range. Compared between the test with automatic titration by EMILY.AI and the test with fixed flow. |
Day 1
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of test time with SpO2 below 88%
Délai: Day 1
|
Percentage of test time (walking and recovery) with SpO2 below 88%, compared between conditions. |
Day 1
|
|
Number of desaturation episodes with SpO2 below 88%
Délai: Day 1
|
Number of episodes per test in which SpO2 falls below 88%, compared between conditions. |
Day 1
|
|
Time to start of oxygen flow correction
Délai: Day 1
|
Time in seconds from SpO2 leaving the target range (88-96%) to the start of an oxygen flow change, compared between conditions. |
Day 1
|
|
Time to return of SpO2 to the target range
Délai: Day 1
|
Time in seconds from SpO2 leaving the target range (88-96%) to its return to the range, compared between conditions. |
Day 1
|
|
Percentage of test time with oxygen delivered while SpO2 is above 92%
Délai: Day 1
|
Percentage of test time (walking and recovery) during which oxygen is delivered while SpO2 is above 92%, compared between conditions. |
Day 1
|
|
Number of episodes with oxygen delivered while SpO2 is above 92%
Délai: Day 1
|
Number of episodes per test in which oxygen is delivered while SpO2 is above 92%, compared between conditions. |
Day 1
|
|
Total oxygen delivered
Délai: Day 1
|
Total volume of oxygen delivered (litres) during each test including recovery, compared between conditions. |
Day 1
|
|
Mean oxygen flow
Délai: Day 1
|
Mean oxygen flow (litres per minute) delivered during each test including recovery, compared between conditions. |
Day 1
|
|
Six-minute walk distance
Délai: Day 1
|
Distance walked (metres), compared between conditions. |
Day 1
|
|
Change in dyspnoea measured with the modified Borg Dyspnoea Scale
Délai: Day 1: before and immediately after each six-minute walk test
|
Change from the start to the end of each test in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome. Compared between conditions. |
Day 1: before and immediately after each six-minute walk test
|
|
Maximum heart rate
Délai: Day 1
|
Maximum heart rate (beats per minute) during each test, compared between conditions. |
Day 1
|
|
Maximum respiratory rate
Délai: Day 1
|
Maximum respiratory rate (breaths per minute) during each test, compared between conditions. |
Day 1
|
|
Perceived difference in exercise capacity between the two tests
Délai: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Did you notice differences in your exercise capacity in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Perceived difference in breathlessness between the two tests
Délai: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Did you notice differences in shortness of breath in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Perceived difference in comfort of oxygen delivery between the two tests
Délai: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Did you notice differences in the comfort of oxygen delivery in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Preference between the two oxygen delivery systems
Délai: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Do you prefer either of the two oxygen systems used in the tests?", and, if so, which one. Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Preference for continuous automatic flow regulation at home
Délai: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to regulate the oxygen flow continuously?". Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
|
Preference for telemonitored home oxygen
Délai: Day 1: within 1 hour after the second six-minute walk test
|
Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to be telemonitored by the medical team?". Categorical 3-option response, not a scored scale. |
Day 1: within 1 hour after the second six-minute walk test
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Sarah Beatrice Heili Frades, MD, PhD, MD, PhD, Hospital Universitario Fundación Jiménez Díaz
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladie chronique
- Attributs de la maladie
- Maladies des voies respiratoires
- Maladies pulmonaires
- Maladies pulmonaires obstructives
- Hypertension
- Conditions pathologiques, signes et symptômes
- Maladie pulmonaire obstructive chronique
- Maladies pulmonaires interstitielles
- Hypertension pulmonaire
Autres numéros d'identification d'étude
- FJD-EMILY-23-02-TM6M
- FJD-EMILY-23-02 (Autre identifiant: Aether Tech SL)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .